LLLotte Sahin Levison

Lotte Sahin Levison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lotte Sahin Levison has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High-frequency nerve ultrasound in Guillain-Barré syndrome

    by Jesper Helbo Storgaard, Erisela Qerama, Anders Stouge, Hatice Tankisi, Thomas Harbo, Henning Andersen, Lotte Levison

  • Hospital-Diagnosed Traumatic Head Injury and Associated Risk of Developing ALS

    by Lotte Levison, Peter Jepsen, Jakob Udby Blicher, Henning Andersen

    Previous studies have suggested that traumatic head injury (THI) may be a risk factor of amyotrophic lateral sclerosis (ALS) development, yet the association remains unclear. We aimed to determine whether hospital-diagnosed THI is an important ALS risk factor, and we investigated the magnitude and duration of associated ALS risk. In this population-based case-control study, we used individual-level data linkage across nationwide health registers from 1980 to 2021 to identify patients with hospital-diagnosed ALS. Each patient was matched 1:10 with individuals from the general population by age, sex, and diagnostic index date. We used conditional logistic regression to examine the relative risk of ALS associated with having previous hospital-diagnosed THI. To avoid the effect of reverse causation, we investigated ALS risk within several time windows and repeated all analyses after restricting THI exposures to more than 3 years before the date of ALS diagnosis. THI was observed in 4.7% of 5,943 ALS cases vs 3.7% of 59,426 controls, with a matched odds ratio (OR) of 1.3 (95% CI 1.1-1.4). However, the risk of ALS declined considerably with increasing time since head injury, with a high OR of 4.5 (95% CI 2.8-7.3) observed within the 6 months before ALS diagnosis. If head injury was suffered 6-12 months before ALS diagnosis, the OR was 2.4 (95% CI 1.4-4.0). Restricting the analysis to THI suffered more than 3 years before ALS diagnosis, we found no association with an OR of 1.1 (95% CI 1.0-1.3). Although a strong association of ALS with THI experienced ≤1 year before ALS diagnosis was evident, our results suggest that this is due to reverse causation. When restricting the analysis to a period deemed relevant for causative events leading to ALS development, no association was observed. Consequently, we do not consider THI an important ALS risk factor. This study was limited by the inability to consider minor THIs not receiving hospital attendance. Future research should explore alternative models to unfold this possible ALS risk factor.


  • Mortality in Myasthenia Gravis in Denmark From 1985 to 2020

    by Josefine Jul Jarbæk Nielsen, Lotte Levison, Henning Andersen

    Myasthenia gravis (MG) is a life-threatening disease associated with elevated mortality, primarily in the first years after diagnosis. We determined short-term (<1 year) and long-term (1-5 years) mortality for patients with MG compared with the general population. Using nationwide health registers, we identified patients with MG and matched 1:10 with the general population by age, sex, and diagnostic index date from 1985 to 2020. We calculated matched hazard ratios (HRs) using Cox regression analysis, stratified by sex, age, period, and baseline comorbidities, and performed comorbidity-adjusted analyses. Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years. Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5). Short-term mortality rose from 2015 to 2020, especially in patients aged 75 years or older (HR 2.8, 95% CI 1.8-3.6). Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population. MG mortality remains elevated, especially in the first year after diagnosis in older patients, underlining the importance of early intervention and close monitoring.


  • Open Access

    Correction: Incidence and mortality of ALS: a 42-year population-based nationwide study

    by Lotte Sahin Levison, Jakob Udby Blicher, Henning Andersen


  • Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021

    by Josefine Jul Jarbæk Nielsen, Lotte Levison, Henning Andersen

    Previous studies on incident myasthenia gravis (MG) have shown inconsistent results. In this study, we determined the MG incidence rates (IRs) over a 36-year period to detect potential trends in MG incidence over time and for different age groups. In this nationwide population-based study from 1985 to 2021, we identified patients aged 18 and older with a primary MG diagnosis in the Danish National Patient Registry. The patients were categorized into 3 distinct groups defined by age at onset: early-onset (≤50 years of age), late-onset (>50 and ≤65 years of age), and very late-onset (>65 years of age). MG IRs were calculated and stratified by sex and time periods in the specified age groups. To increase the validity of the MG IRs, we performed sensitivity analyses from 1995 until 2021, adding ≥2 prescriptions of pyridostigmine and/or acetylcholine receptor seropositivity. We identified 2,110 patients with MG (1,060 women), with a median age of 57.1 (interquartile range [IQR] 40.2-74.0) years for women and 63.6 (IQR 56.4-74.3) years for men. In the study period, the MG IR was 1.4 (95% CI 1.3-1.4) per 100,000 person-years, which persisted in our sensitivity analyses, with no significant differences between the sexes. Overall, 579 patients (27.4%) were classified as early-onset, 490 (23.2%) as late-onset, and 1,040 (49.3%) as very late-onset. For early-onset MG, the IR was 0.7 (95% CI 0.6-0.7) and remained stable throughout the study period. Inversely, the IRs for late-onset and very late-onset MG increased over time, with corresponding incidence rate ratios (IRRs) of 1.9 (95% CI 1.3-2.6) and 2.2 (95% CI 1.7-2.9), from the first 5 years from 1985 to 1990 until the last 6 years of the study period from 2015 to 2021. The overall IR of MG increased from 1985 to 2021, aligning with recent reports from neighboring European countries. The most significant rise occurred during the last 6 years of the study period compared with the first 5 years, with an IRR reaching 1.9 (95% CI 1.6-2.3). This increase in IRs was observed only in the late-onset and very late-onset age groups.


  • Open Access

    Incidence and mortality of ALS: a 42-year population-based nationwide study

    by Lotte Sahin Levison, Jakob Udby Blicher, Henning Andersen

    Background and aim Recent studies have suggested that the incidence rate (IR) and the rate of death (MR) of amyotrophic lateral sclerosis (ALS) are increasing. Still, it remains unclear whether this is due to improved case ascertainment or represents a true increase. We examined the development in the incidence and mortality of ALS in Denmark for 42 years. Methods We retrieved individual-level data of all patients aged above 18 years with first-time ALS diagnosed at any Danish department of neurology. The IR and MR were calculated based on data from 1980 to 2021, stratified by gender and age. Results We identified 5,943 patients with ALS and identified a total of 5,069 deaths in the nationwide population. Overall, the IR was 3.4 per 100,000 persons per year (95% CI 3.4–3.5). ALS incidence rose gradually during the study period, and the IR was 2.8 times higher (95% CI 2.4–3.2) when comparing the latest period (2018–2021) with the first (1980–1983). Parallel to the IR, the MR increased over time and was associated with male gender and rose with age at diagnosis, peaking in the 70–79-year age group. Conclusion In Denmark, the IR and MR of ALS increased threefold from 1980 to 2021, with steadily increasing risk related to male gender and in particular to higher age. Considering our aging societies, the number of elderly patients with ALS can be expected to increase considerably.


  • Open Access

    Registration of Amyotrophic Lateral Sclerosis: Validity in the Danish National Patient Registry

    by Lotte Sahin Levison, Peter Jepsen, Henning Andersen

    Purpose: Health care databases are a valuable source for epidemiological research on amyotrophic lateral sclerosis (ALS) if diagnosis codes are valid. We evaluated the validity of the diagnostic codes for ALS in the Danish National Patient Registry (DNPR). Patients and Methods: We obtained data from the DNPR for all adult (> 17 years) patients registered with ALS in Denmark between 1987 and 2022 (median population of 4.2 million during the study period). We randomly selected adult patients living in the North Denmark Region and Central Denmark Region (median population 1.4 million), with a primary discharge diagnosis code of ALS, diagnosed at three departments of neurology. We retrieved and reviewed medical records and estimated the positive predictive value (PPV) of the ALS diagnosis. Results: Over 36 years, we identified 5679 patients. From the validation cohort of 300 patients, we were able to retrieve 240 (80%) medical records, and 215 ALS diagnoses were confirmed. The overall positive predictive value was 89.6% (95% confidence interval (CI): 85.1– 92.8). The highest PPV was achieved for diagnoses registered for patients aged ≥ 70 years (93.8; 95% CI: 86.2– 97.3) compared to patients < 60 years (83.4; 95% CI: 73.3– 90.7). Conclusion: We found a high PPV of primary diagnostic codes for ALS from Danish departments of neurology, demonstrating high validity. Thus, the DNPR is a well–suited data source for large-scale epidemiological research on ALS.


  • Open Access

    Hospital‐diagnosed morbidities and recent surgery as risk factors for developing Guillain–Barré syndrome

    by Lotte S. Levison, Reimar W. Thomsen, Henning Andersen

    Background and purpose: This study was undertaken to determine the association of hospital‐diagnosed morbidity and recent surgery with risk of subsequent Guillain–Barré syndrome (GBS) development.Methods: We conducted a nationwide population‐based case–control study of all patients with first‐time hospital‐diagnosed GBS in Denmark between 2004 and 2016 and 10 age‐, sex‐, and index date‐matched population controls per case. Hospital‐diagnosed morbidities included in the Charlson Comorbidity Index were assessed as GBS risk factors up to 10 years prior to the GBS index date. Incident major surgery was assessed within 5 months prior.Results: In the 13‐year study period, there were 1086 incident GBS cases, whom we compared with 10,747 matched controls. Any pre‐existing hospital‐diagnosed morbidity was observed in 27.5% of GBS cases and 20.0% of matched controls, yielding an overall matched odds ratio (OR) of 1.6 (95% confidence interval [CI] = 1.4–1.9). The strongest associations were found for leukemia, lymphoma, diabetes, liver disease, myocardial infarction, congestive heart failure, and cerebrovascular disease, with 1.6‐ to 4.6‐fold increased risks of subsequent GBS. GBS risk was strongest for morbidities newly diagnosed during the past 5 months (OR = 4.1, 95% CI = 3.0–5.6). Surgical procedures within 5 months prior were observed in 10.6% of cases and 5.1% of controls, resulting in a GBS OR of 2.2 (95% CI = 1.8–2.7). Risk of developing GBS was highest during the first month following surgery (OR = 3.7, 95% CI = 2.6–5.2).Conclusions: In this large nationwide study, individuals with hospital‐diagnosed morbidity and recent surgery had a considerably increased risk of GBS.


  • Open Access

    Increased risk of depression after Guillain‐Barré syndrome

    by Lotte Sahin Levison, Reimar Wernich Thomsen, Henning Andersen

    Introduction/AimsGuillain-Barre syndrome (GBS) is a potentially life-threatening disorder, and some patients may develop subsequent depression related to traumatic stress or permanent loss of motor function. We determined the short-term (0 to 2 years) and long-term (>2 years) risk of depression after GBS. MethodsIndividual-level data from nationwide registries were linked in this population-based cohort study of all first-time hospital-diagnosed GBS patients in Denmark between 2005 and 2016 and individuals from the general population. After exclusion of individuals with previous depression, we computed cumulative rates of depression, defined as either antidepressant drug prescription or depression hospital diagnosis. We used Cox regression analyses to calculate adjusted depression hazard ratios (HRs) after GBS. ResultsWe identified 853 incident GBS patients and recruited 8639 individuals from the general population. Depression within 2 years was observed in 21.3% (95% confidence interval [CI], 18.2% to 25.0%) of GBS patients and in 3.3% (95% CI, 2.9% to 3.7%) of those in the general population, resulting in a HR of 7.6 (95% CI, 6.2 to 9.3). The highest depression HR was observed within the first 3 months after GBS (HR, 20.5; 95% CI, 13.6 to 30.9). After the first 2 years, GBS patients and the general population members had similar long-term depression risks with an HR of 0.8 (95% CI, 0.6 to 1.2). DiscussionDuring the first 2 years after GBS hospital admission, patients with GBS had a 7.6-fold increased hazard of depression compared with individuals in the general population. Two years after GBS, the risk of depression was similar to that of the background population.


  • Open Access

    Guillain–Barré syndrome following influenza vaccination: A 15‐year nationwide population‐based case–control study

    by Lotte Sahin Levison, Reimar Wernich Thomsen, Henning Andersen

    Background and purpose: Influenza vaccination may increase the risk of developing Guillain–Barré syndrome (GBS) due to an elicited immune response, but the exact magnitude and duration of risk is unclear and hence the aim of this study.Methods: We conducted a retrospective nationwide population‐based case–control study of prospectively collected data on all patients with first‐time hospital‐diagnosed GBS in Denmark between 2002 and 2016 and 10 age‐, sex‐ and index date‐matched population controls per case. The primary exposure was incident influenza vaccination 1 month prior to admission with GBS. We used medical registries to ascertain a complete hospital contact history of pre‐existing morbidities. To examine duration of GBS risk, we repeated the analysis for five consecutive 1‐month risk periods following vaccination.Results: Of the 1295 GBS cases and 12,814 controls, 20 cases (1.5%) and 119 controls (0.9%) had received an influenza vaccination within the last month, yielding a comorbidity‐adjusted odds ratio of 1.9 (95% confidence interval 1.1–3.2) for GBS. Stratified analyses by calendar time, gender and age showed similar results. The increased risk of GBS was largely confined to 1 month following influenza vaccination. The population‐attributable fraction of GBS from influenza vaccination in Denmark was 0.4%.Conclusions: Influenza vaccination was associated with a slightly elevated risk of GBS occurrence within 1 month after vaccination. However, only 1.5% of GBS cases in Denmark are associated with recent influenza vaccination. Thus, the benefit of influenza vaccines in preventing influenza infections and associated morbidity and mortality needs to be weighed against the small absolute risk of GBS.